Le Lézard
Classified in: Health
Subject: SVY

Umbralisib (TG Therapeutics/Rhizen) Drug Overview & Product Profiles 2017-2018 & 2019-2026


DUBLIN, July 15, 2019 /PRNewswire/ -- The "umbralisib" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.

Umbralisib has a unique chemical structure that confers greater specificity to target sites and may produce equivalent or improved efficacy, along with a more favorable safety profile, in comparison to other PI3K inhibitors such as Zydelig (idelalisib; Gilead) or Copiktra (duvelisib; Verastem) in non-Hodgkin's lymphoma.

Analyst Outlook

TG Therapeutics is developing its phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as part of a combination with its in-house cluster of differentiation (CD)20-targeted antibody, ublituximab. The combination is being evaluated in the Phase II/III UNITY-NHL trial (ClinicalTrials.gov identifier: NCT02793583) for the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL) patients, including diffuse large B-cell lymphoma (DLBCL) patients.

The combination has demonstrated early signs of efficacy, but significant adverse events potentially tied to PI3K inhibition, such as neutropenia, remain a concern. As such, umbralisib's uptake may be limited by its side-effect profile, the potentially high cost of a combination regimen with ublituximab, and strong forecasted competition from approved regimens and several late-phase competitors targeting the relapsed or refractory patient segment.

Key Topics Covered:

OVERVIEW
Drug Overview
Product Profiles
umbralisib : NHL: Follicular lymphoma (FL)
umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL)

LIST OF FIGURES
Figure 1: Umbralisib for follicular lymphoma - SWOT analysis
Figure 2: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 3: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country, 2017-26
Figure 4: Umbralisib for diffuse large B-cell lymphoma - SWOT analysis
Figure 5: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 6: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017-26

LIST OF TABLES
Table 1: Umbralisib drug profile
Table 2: Umbralisib ongoing pivotal trials in follicular lymphoma
Table 3: Umbralisib clinical trial data in follicular lymphoma
Table 4: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017-26
Table 5: Umbralisib drug profile
Table 6: Umbralisib ongoing pivotal trial in diffuse large B-cell lymphoma
Table 7: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/j9r709

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



SOURCE Research and Markets


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: